Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background/aim: Serum thymidine kinase 1 (STK1) is a proliferation biomarker that has been used as a diagnostic marker of several malignant diseases. However, there are limited data for prostate cancer (PCa).
Patients And Methods: In this study, we retrospectively analysed serum samples from 169 patients with biopsy confirmed PCa, who had been indicated for radical prostatectomy (RP) between 2013-2016. The results were compared with those in serum samples from 39 healthy men. We used commercially available enzymatic immunoassay to determine the levels of STK1. The patients were divided into groups according to the Gleason score (GS) and risk factors for adjuvant radiotherapy (aRT), which were defined as GS 8-10, pT3, and a positive surgical margin.
Results: The median serum level of STK1 in PCa patients was 0.289 pmol/l. In the control group, the median value was 0.0116 pmol/l (p<0.001). By comparing the patients with GS≤6 vs. 7 vs. ≥8 (p=0.01), we found statistically significant differences. In the correlation of STK1 values with risk factors, we found statistically significant differences both in comparison of 0 vs. 1 vs. 2 vs. 3 risk factors (p=0.021), as well as ≤1 vs. 2≥ risk factors (p=0.009).
Conclusion: The levels of STK1 are significantly higher in patients with PCa than those in healthy controls. Furthermore, STK1 values correlate with GS and predefined risk factors for aRT. Therefore, STK1 can be considered as a potential tumour marker of PCa diagnosis and risk stratification.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.21873/anticanres.16319 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Predictive levels of vascular endothelial growth factor (VEGF), thymidine kinase 1 (TK1) with interleukin-6 (IL-6), plasma T cells, NK cells as well as B cells in treating diffuse large B-cell lymphoma receiving rituximab.
J Med Biochem
July 2025
Lujiang County People's Hospital, Department of Oncology, Anhui Hefei, China.
Background: The aim was to explore the effect of rituximab in combination with chemotherapy in treating diffuse large B-cell lymphoma and levels of vascular endothelial growth factor (VEGF), thymidine kinase 1(TK1) with interleukin-6 (IL-6), plasma T cells, NK cells as well as B cells.
Methods: Eighty patients admitted to Lujiang County People's Hospital from January 2022 to January 2024 were included. The control group accepted cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy regimens.
Evaluation of thymidine kinase 1 and folate receptor alpha as potential biomarkers in prostate cancer.
Sci Rep
August 2025
Department of Clinical Pathology, National Cancer Institute, Cairo University, Cairo, Egypt.
Prostate cancer is a widespread malignancy with high mortality rates. Therapeutic success depends on clinical biomarkers for early detection and progression of the disease. The study aimed to assess the potential role of Thymidine Kinase one (TK1) and folate receptor alpha (FORα) in prostate cancer.
View Article and Find Full Text PDFTemporal optimization of CD25-biased IL-2 agonists and immune checkpoint blockade leads to synergistic anticancer activity despite robust regulatory T cell expansion.
J Immunother Cancer
August 2025
Laboratory of Tumor Immunology, Institute of Microbiology of the Czech Academy of Sciences, Prague, Czech Republic
Background: Interleukin-2 (IL-2) immunotherapy can induce durable tumor remissions, but its clinical performance has been limited by significant drawbacks such as short serum half-life and high toxicity. Administration of IL-2 in complex with certain anti-IL-2 antibodies (IL-2cx) enhances circulation half-life while also selectivity directing the cytokine to particular immune cell subsets. In particular, IL-2cx has been developed that targets either cells expressing the CD25-containing high-affinity IL-2 receptor (ie, CD25-biased IL-2cx) or cells expressing the CD25-lacking intermediate-affinity IL-2 receptor (ie, CD25-blocking IL-2cx).
View Article and Find Full Text PDFSerum Markers as predictors for treatment benefit in castration-resistant prostate cancer.
Urol Oncol
August 2025
Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden; Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden. Electronic address:
Purpose: While most prostate cancer patients initially respond to androgen-deprivation therapy (ADT), they will develop castration-resistance leading to progressing to castration-resistant prostate cancer (CRPC). Different treatment options are available for CRPC, including androgen receptor pathway inhibitors (ARPIs) and docetaxel (DOC). As tissue samples are difficult to access at this stage, blood-based analyses offer a more feasible approach.
View Article and Find Full Text PDFA visualized machine learning model using noninvasive parameters to differentiate men with and without prostatic carcinoma before biopsy.
Sci Rep
July 2025
, Shenzhen, 518110, China.
This study aimed to create a visualized extreme gradient boosting (XGBOOST) model to distinguish prostatic carcinoma (PCA) from non-PCA using noninvasive prebiopsy parameters before biopsy. This was a cross-sectional study of 310 Chinese men who underwent prostate biopsy and were divided into PCA (n = 126) and non-PCA (n = 184) groups. The non-PCA patients were diagnosed with benign prostatic hyperplasia (BPH) based on biopsy results.
View Article and Find Full Text PDF